On November 8th, 2023, the National Medical Product Administration (NMPA) of China made an announcement that Inaticabtagene Autoleucel had been approved for the treatment of
Carteyva (Relmacabtagene Autoleucel Injection), an anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product has been approved for the treatment of adult patients with
Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. The immune system helps your body fight infections and other diseases.
The anti-PD-1 immuno-oncology drug star nivolumab has won the race to the world’s first regulatory checkered flag for approval. Ono Pharmaceutical, which picked up the